New presentations include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion, as well...
MURFREESBORO, TN / ACCESS Newswire / February 2, 2026 / National Health Investors, Inc. (NYSE:NHI) announced today that it invested...
Planned share-based transaction is expected to be completed during the first fiscal quarter of 2026 Vireo plans to appoint Chris...
NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the fourth quarter ended December 31,...
SHELTON, CONNECTICUT / ACCESS Newswire / January 13, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...
Raanana, Israel, Jan. 02, 2026 (GLOBE NEWSWIRE) -- As the 2025-2026 flu season intensifies across the United States, a mutated...
Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma Approval based on...
Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved...
Transaction will expand Vireo’s operating footprint to 10 states with 166 dispensaries and approximately 800,000 sq. ft. of cultivation and...
MINNEAPOLIS, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (“Vireo”) (CSE: VREO; OTCQX: VREOF) (“Vireo” or the “Company”) today...
MURFREESBORO, TN / ACCESS Newswire / December 18, 2025 / National Health Investors, Inc. (NYSE:NHI) announced today that it has...
Acquired assets further optimize Vireo’s operating footprint in Colorado with addition of 17 dispensaries Transaction expands Vireo’s leadership position in...
Daix (France), New York City (New York, United States), November 28, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”),...
Approval based on results of landmark Phase 3 C-POST trial that show Libtayo is first immunotherapy to significantly improve disease-free...
SHELTON, CONNECTICUT / ACCESS Newswire / November 14, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...
Proof-of-concept trials confirm robust anti-clotting effects for Regeneron’s two mechanistically-distinct antibodies against factor XI, in patients undergoing total knee replacement...
Q3 2025 financial results ahead of expectations. Announces more than $500 million in newly-contracted annualized revenue to launch in 2026....
MURFREESBORO, TN / ACCESS Newswire / November 6, 2025 / National Health Investors, Inc. (NYSE:NHI) announced today that it will...
LAFAYETTE, LA / ACCESS Newswire / November 5, 2025 / Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), an in-home...
NV-387 Could be the Answer to the MPox Clade I Rising in the USA, Says Dr. Diwan SHELTON, CONNECTICUT /...